The 2025 FDD shows an unusual structural advantage: no initial franchise fee and a fixed monthly license option tied to pharmaceutical purchasing. The strongest burden is the absence of an exclusive territory across physical and digital channels. These trade-offs are conditional and do not support a buy-or-reject recommendation.
Data basis. Medicine Shoppe International, Inc. issued the U.S. Franchise Disclosure Document on September 18, 2025. This analysis covers new retail stores, conversions of existing pharmacies, and full-brand or Co-Brand Addendum use under the Franchise Agreement, Inventory Purchase Addendum, Medicine Shoppe InterNet® agreements, and selected Retail Solutions agreements. Items 1, 3–8, 10–12, 15–17, and 19–22 were reviewed.
Item 19 contains no financial performance representation; Item 20 covers fiscal years ended June 30, 2023 through 2025. The official U.S. franchise page and other official sources were checked July 30, 2026. Contract terms control where web copy is broader: public pages may describe headline features or participating-location services without stating every purchase condition, legacy exception, affiliate dependency, state-law qualification, adoption rate, or unit-level economic result. No franchise-controlled public copy of the 2025 FDD was located, so FDD citations are unlinked.
These figures are not scores and should not be read as equally important. A modest transfer fee can matter less than staffing coverage, supplier economics, or exit rights, while a longer manual does not establish the quality, timing, or usefulness of assistance. Each figure is best treated as a contract or workload indicator and tested against the proposed location, transaction, management team, capital structure, and operating assumptions.
Which Medicine Shoppe features can help, and where can they create friction?
The most buyer-relevant features are dual-edged. The license-fee structure, optional service menu, owner-role flexibility, channel rights, disclosure limits, and mutual termination provisions can each improve one type of flexibility while shifting execution, dependency, or evidence risk to the buyer’s operating plan.
License fee depends on inventory sourcing
Verified fact: MSI charges 3% of Gross Sales, or $599 monthly when the pharmacy commits to buy at least 95% of pharmaceutical inventory from Cardinal Health or an affiliate.
Retail Solutions are modular, not open-ended
Verified fact: Selected Retail Solutions receive a $300 monthly credit, generally require one year and 30–90 days’ notice, and do not include a formal MSI training program.
Owner participation is flexible; pharmacist coverage is not
Verified fact: The owner need not participate personally, but the business must always be supervised by a licensed pharmacist and every employed pharmacist must hold required state licenses.
Territory is nonexclusive across stores, customers, and channels
Verified fact: The Franchise Agreement authorizes one location without an exclusive territory; MSI, affiliates, Medicine Shoppe franchisees, and Medicap Pharmacy franchisees may solicit customers through any channel.
Item 19 supplies no system performance benchmark
Verified fact: Item 19 contains no financial performance representation, and MSI disclaims past or future performance claims except actual records for a specific existing outlet under consideration.
Termination flexibility is mutual
Verified fact: The five-year agreement renews absent six-month notice and lets either party terminate without cause on 90 days’ notice, subject to exceptions and state law.
What does the three-year outlet record show?
The disclosed Medicine Shoppe footprint contracted across all three fiscal-year tables. That direction warrants explanation, but it does not identify the cause of each departure or establish that an individual outlet failed. Transfers are ownership changes and must be separated from terminations, nonrenewals, and other cessations.
Interpretation: The table reconciles from 310 to 271 outlets, a net reduction of 39. Across the period, 33 openings were offset by 64 terminations, two nonrenewals, and six outlets that ceased for other reasons; 32 transfers did not change outlet count.
Source: 2025 FDD, Item 20, Tables 1–4, pp. 40–45. “Other reasons” is the FDD category; it should not be relabeled as failure without outlet-specific evidence.
Exhibit Z lists 41 retail franchisees and three closed-door pharmacy franchisees that transferred, terminated, were not renewed, otherwise stopped operating, or met another listed condition during fiscal 2025. The next diligence step is to classify those contacts by event, state, format, ownership tenure, and whether the pharmacy continued independently.
How far apart are the new-store and conversion investment ranges?
The conversion path begins substantially lower because it assumes an operating pharmacy already owns much of the needed infrastructure. That comparison is incomplete for an acquisition: the disclosed conversion range excludes the negotiated purchase price for prescription files, goodwill, and any covenant not to compete.
Interpretation: Format selection changes the disclosed capital range, but the range is not a valuation of an existing pharmacy. New-store working capital also assumes an owner-operator at the low end, while MSI offers no direct or indirect financing and does not guarantee debt.
Source: 2025 FDD, Item 7, pp. 15–18; Item 10, p. 24. The totals exclude finance charges, interest, debt service, and acquisition consideration not listed in Item 7.
Where does MSI provide structure, and where does the buyer retain execution risk?
MSI and Cardinal Health affiliates arrange defined systems, payer-network access, brand standards, selected data tools, and optional services. The franchisee retains the pharmacy’s site, financing, employees, training, professional judgment, legal compliance, local advertising, and day-to-day results. The boundary is operationally material because pharmacy regulation cannot be delegated to the franchisor.
Provided or arranged
- Medicine Shoppe System
- Marks, standards, policies, a 90-page Operations Manual, and approved-site control.
- Medicine Shoppe InterNet®
- Required participation in arranged payer and pharmacy-benefit relationships, subject to network terms.
- Retail Solutions
- Selectable reimbursement, reconciliation, compliance, inventory, marketing, payment, and clinical-service programs.
- Cardinal Health affiliates
- Wholesale inventory access, private-label products, technology services, and other separately priced programs.
Retained by the buyer
- Licensed operation
- Pharmacist supervision, employee licensing, controlled-substance compliance, and professional judgment.
- Opening execution
- Site selection, lease, build-out, financing, permits, equipment installation, staffing, and employee training.
- Local demand
- Advertising spend, pricing, customer acquisition, service selection, and market positioning within brand rules.
- Data and vendors
- HIPAA-secure systems, required internet access, vendor upgrades, and review of affiliate data-sharing rights.
Sources: 2025 FDD, Items 1, 8, 11, 15–16; Franchise Agreement §§II, IV–V; Business Associate Agreement. Cardinal Health’s May 2026 community-pharmacy discussion identifies margin, staffing, and regulatory pressures that make these retained responsibilities economically relevant.
The FDD cover includes a special risk statement that MSI’s financial condition calls into question its ability to provide services and support. Item 21 separately states that Cardinal Health guarantees MSI’s obligations and supplies audited Cardinal Health financial statements. Buyers should obtain the current guarantee and ask counsel which claims, services, damages, and affiliates it actually covers.
Which buyers may align with this operating structure?
Alignment depends less on franchise enthusiasm than on pharmacy-specific operating capacity. The model places more weight on a buyer’s licensed staffing, reimbursement knowledge, wholesale analysis, local marketing, and contract administration than on franchisor-led training, exclusive geography, financing, or disclosed unit-performance averages.
More aligned profile
A pharmacist-owner, experienced community-pharmacy operator, or disciplined multi-location group with an established pharmacist bench, independent financing, local demand knowledge, and the ability to compare Cardinal Health purchasing economics against the 3% Gross Sales alternative. This profile can use Retail Solutions selectively without treating them as substitutes for management.
More likely to experience friction
A hands-off buyer without licensed management depth; a first-time pharmacy entrant expecting site sourcing or formal training; or an operator requiring protected territory, system-funded advertising, franchisor financing, or an Item 19 benchmark. Friction also rises when the buyer cannot tolerate affiliate purchasing dependence or mutual 90-day termination exposure.
What should be verified before signing?
The highest-value diligence questions test the fee-and-supply relationship, licensed staffing resilience, local channel conflict, outlet departures, optional service economics, and contract exit mechanics. Each answer should be tied to the buyer’s exact format, state, site, ownership structure, and proposed supplier arrangement.
Economics and evidence
Operations and local market
Contract and current disclosure
The strongest structural advantage is a configurable relationship that combines a low fixed license option, payer-network participation, and selectable pharmacy services. The most material burden is that territory, supplier, staffing, and contract flexibility remain constrained or interdependent. An experienced pharmacy operator with licensed coverage and wholesale-analysis capability is more aligned; a hands-off entrant seeking protected geography or performance benchmarks may face friction. The highest-priority fact to verify is the all-in economic effect of the inventory commitment compared with the percentage-fee alternative.